Neurostimulation Market Surges with a Promising CAGR of 9.5% through 2033, Projected to Reach a Valuation of US$ 15,417.4 Million | Future Market Insights Inc.

Key Players Providing Neurostimulation Devices Equipped with Latest Technology to Deliver Results for Patients with Chronic Pain. FMI Forecasts US$ 15,417.4 million Market Valuation by 2033.

NEWARK, DEL, Nov. 14, 2023 (GLOBE NEWSWIRE) -- The global neurostimulation market value is expected to rise from US$ 6,221.2 million in 2023 to US$ 15,417.4 million by 2033. This estimated growth is expected to be driven by a healthy CAGR of 9.5% in the global neurostimulation market over the next decade.

Increasing cases of chronic pain continue to pave the growth of the neurostimulation market. In the United States, 1 in 5 people report they are suffering from chronic pain, as per the latest estimates from National Institutes of Health. By opting for neurostimulation therapy, patients can take charge of their pain and enjoy a better quality of life.

Many research studies are being conducted to cover the full potential of neurostimulation in treating multiple disorders. For instance, in 2022, a study found that the efficiency of restorative neurostimulation in treating lower back pain originating from multifidus dysfunction. The efficiency of this therapy stays intact for three years.

Request for a sample of this research report:

Latest research on Parkinson’s disease has revealed that neuromodulation technologies can be used to mitigate some of the incapacitating symptoms like rigidity and tremors. Since the disease is impacting a growing number of people and putting a strain on healthcare systems, families, and economies, new advancements in neurostimulation to manage Parkinson’s disease are predicted to be beneficial for the neurostimulation market.

“Increasing government support to drive advancement in the medical field, along with high growth prospects in the Asia Pacific, are motivating key players to concentrate their efforts on targeting a market in the region. Apart from this, participants are partnering with domestic players and distributors to enjoy easy access to emerging markets in the future,” opines Sabyasachi Ghosh Associate Vice President at Future Market Insights (FMI).

Key Takeaways from the Neurostimulation Market Report

  • India and China are emerging as robust market players, expanding at CAGRs of 14.3% and 12.4%, respectively, through 2033.
  • Australia is predicted to exhibit high potential for growth. FMI analysts have estimated that the neurostimulation market in Australia is going to witness a CAGR of 10.5% through 2033.
  • The United States accounts for the leading market share. As per the latest study, the neurostimulation market in the United States is expected to be 40.3% in 2023.
  • Germany is predicted to lead the market in Europe. The country is anticipated to acquire a 4.2% share of the overall market.
  • Pain management segment acquires 45.3% value in the global market.
  • Spinal cord stimulator records market share of 52.3% in 2023.

Key Players:

  • Boston Scientific Corporation
  • Cyberonics Inc.
  • St. Jude Medical Inc.
  • Medtronic Inc.
  • NeuroPace Inc.
  • NeuroSigma, Inc.
  • Others

Key Developments Taking Place in the Neurostimulation Market

  • In August 2023, the University of Glasgow published the latest brain stimulation project on their site. The project aims to develop revolutionary methods to treat a wide array of neurological conditions. Researchers from Glasgow are going to partner with colleagues from Italy, Germany, Finland, and Spain to develop BRAINSTORM technology, that could provide better results via less invasive techniques.
  • In September 2023, an implanted restorative neurostimulation clinical trial, after its three-year follow-up found out that ReActiv8 (Mainstay Medical) is effective and safe.
  • In October 2022, a review demonstrated that neurostimulation can show effective results in the treatment of dysphagia.

Purchase Now to Access Segment-specific Information and uncover Key Trends, Drivers, and Challenges:

Key Segmentations:

By Type:

  • Spinal Cord Stimulators
  • Deep Brain Stimulators
  • Sacral Nerve Stimulators
  • Vagus Nerve Stimulators
  • Others

By Application:

  • Pain Management
  • Hearing Loss
  • Urinary Incontinence
  • Parkinson's disease
  • Epilepsy
  • Others

By Region:

  • North America
  • Latin America
  • Asia Pacific
  • Japan
  • Western Europe
  • Eastern Europe
  • Middle East & Africa

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

Explore FMI’s related ongoing Coverage in the Healthcare Market Insights Domain:

MRI-Safe neurostimulation systems market will expand at a CAGR of 15.3% between 2023 and 2033, totaling around US$ 1,158.9 million by 2033.

The global neurotrophic keratitis treatment market is slated to reach a valuation of US$ 5 billion in 2023. According to Future Market Insights, the market is expected to grow at a 7.17% CAGR until 2033, valued at US$ 10 billion.

The neurointerventional Device market size is projected to be worth US$ 2.6 billion in 2023. The market is likely to reach US$ 4.1 billion by 2033. The market is further expected to surge at a CAGR of 4.7% during the forecast period 2023 to 2033.

The neurodegenerative disease market is anticipated to register a CAGR of 7% during the forecast period, reach a valuation of US$ 92 Billion by 2032.

The global neuroendocrine carcinoma treatment market to grow at a CAGR of 8.0% through 2029.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer, Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Nandini Singh Sawlani  

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware - 19713, USA
T: +1-845-579-5705
For Sales Enquiries:
LinkedInTwitterBlogs | YouTube